Share this Post!

The Policy and Planning Service (PPS) respectfully informs the pharmaceutical stakeholders of the posting of the 5th Draft of the APRF Agreement for inputs/comments. Kindly see the attached electronic copy of the draft agreement in the FDA Website for your reference and information.

All comments shall be sent via email at following the subject format: COMMENTS_DRAFT APRF AGREEMENT. We hope to receive the inputs on or before 31 March 2023 for consolidation and subsequent submission to the ASEAN Secretariat.

For your information and guidance.